CalciMedica, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CALC | CLDI | LSTA | PTN | CVKD | ET80.F | |
|---|---|---|---|---|---|---|
| Market cap | 9.18M | 2.68M | 11.45M | 10.72M | 3.78M | 5.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.8 | -0.8 | -0.9 | -3.2 | -0.3 | — |
| Price/book | 1.5 | 0.5 | 1.2 | 1.6 | 0.8 | 0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −91.21% | −96.88% | −53.42% | −19.69% | −91.14% | −12.33% |
| Today | −8.50% | −2.54% | −2.75% | +15.33% | −6.19% | +0.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CALC news ›CG Oncology grants Isabel Kalofonos 92,000 stock options
CG Oncology (NASDAQ: CGON) is a late-stage biopharma company developing cretostimogene, an intravesical oncolytic immunotherapy for non-muscle invasive bladder cancer. - [Form 4] CG Oncology, Inc. Insider Trading Activity CG Oncology…
Kuya Silver Announces Grant of Stock Options
October 19, 2026 5:08 PM EDT | Source: Kuya Silver Corporation Of the Options, 475,000 have been approved for grant to the Company's independent directors as their annual equity incentive and will expire five years from the Grant Date. The…
CalciMedica grants Glicklich option on 20,000 shares
CalciMedica, Inc. (CALC) is a La Jolla-based clinical-stage biopharma developing CRAC channel inhibitors like Auxora for severe inflammatory diseases. CalciMedica grants Glicklich option on 20,000 shares The option vests in equal monthly…
CalciMedica director Guerard gets 20,000-share option
Frederic Guerard's October 1, 2026 award vests in monthly installments, fully vesting at the 2027 annual meeting. The option expires September 30, 2036. CalciMedica director Guerard gets 20,000-share option The option's monthly vesting…
CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts
Posted by Defense World Staff on Oct 12th, 2026 Get Our Latest Report on CALC CalciMedica (NASDAQ:CALC – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the…
CalciMedica director Allan Shaw gets 20,000 options
CalciMedica, Inc. (CALC) is a La Jolla-based clinical-stage biopharma developing CRAC channel inhibitors like Auxora for severe inflammatory diseases. CalciMedica director Allan Shaw gets 20,000 options The option’s monthly vesting…
CalciMedica CFO Stephen Bardin to resign after Q3 report
Trident Reports First Half 2026 Unaudited Financial Results The timing links Bardin’s departure to the filing of CalciMedica’s quarterly report for the period ended September 30, 2026. Pursuant to Section 13 or 15(d) Date of Report (Date…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- defenseworld.net1
- newsfilecorp.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.